Cornerstone Mulls Next Steps for Lixivaptan After CRL
With government offices still hampered by the cleanup from Hurricane Sandy, the FDA was several days late responding to Cornerstone Therapeutics Inc.'s new drug application for lixivaptan. The decision, reported Thursday, was no shocker.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter